

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No securities may be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Any public offering of securities to be made in the United States will be made by means of a prospectus. Such prospectus will contain detailed information about the company making the offer, its management, as well as financial statements. No public offer of securities is to be made by the Company in the United States.*



## **Yestar Healthcare Holdings Company Limited**

**巨星醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2393)**

**NOTICE OF SCHEME MEETING  
IN THE GRAND COURT OF THE CAYMAN ISLANDS  
FINANCIAL SERVICES DIVISION  
FSD CAUSE NO. 295 OF 2021 (NSJ)  
IN THE MATTER OF SECTION 86 OF THE COMPANIES ACT  
(AS REVISED)  
AND  
IN THE MATTER OF YESTAR HEALTHCARE HOLDINGS  
COMPANY LIMITED  
(巨星醫療控股有限公司)**

This announcement is made by Yestar Healthcare Holdings Company Limited (the “**Company**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Unless otherwise defined herein, terms used in this Notice have the same meanings as in the explanatory statement (the “**Explanatory Statement**”) relating to the proposed scheme of arrangement between the Company and the Scheme Creditors (as defined therein) under section 86 of the Companies Act (As Revised) (the “**Scheme**”).

NOTICE IS HEREBY GIVEN that, by an Order made at the hearing held on 5 November 2021 (the “**Scheme Convening Order**”), the Grand Court of the Cayman Islands (the “**Court**”) has directed that a meeting of Scheme Creditors (the “**Scheme Meeting**”) be convened for the purposes of considering and, if thought fit, approving the Scheme (with or without modification, addition or condition approved or imposed by the Court).

The Scheme Meeting will be held at the offices of Kirkland & Ellis at 26th Floor, Gloucester Tower, The Landmark, 15 Queen’s Road Central, Hong Kong, with any adjournment as may be appropriate, commencing at 7 a.m. (Cayman Islands time)/8:00 p.m. (Hong Kong time) on 3 December 2021 (subject to applicable COVID-19 restrictions, policies or guidance then in force in the applicable jurisdiction, and in which case any changes in arrangements relating to the Scheme Meeting shall be communicated to Scheme Creditors in advance of the Scheme Meeting on the Scheme Website and by a public announcement published on the Stock Exchange). Telephone conference facilities will be made available to Scheme Creditors upon request to the Information Agent allowing Scheme Creditors to listen in to the Scheme Meeting and to ask questions (but not to cast their vote).

All Scheme Creditors are requested to attend the Scheme Meeting at such place and time either in person, by a fully authorised representative (if a corporation) or by proxy. A copy of the Scheme and a copy of the Explanatory Statement are incorporated in the document of which this Notice forms part.

Scheme Creditors may vote in person (or, if a corporation, appoint a duly authorised representative) or appoint proxies to vote in their place. Scheme Creditors may appoint proxies to vote at the Scheme Meeting in Part 2 (*Voting and Appointment of Proxy*) of the Account Holder Letter. However, Scheme Creditors, their duly authorized representatives (if a corporation), or their proxies should they attend via teleconference cannot cast their vote at the Scheme Meeting via telephone.

Neither the Depositary nor the Existing Notes Trustee is expected to vote in respect of the Existing Notes at the Scheme Meeting.

In order to vote on the Scheme and attend the Scheme Meeting (in person, by a duly authorised representative (if a corporation) or by proxy), a Scheme Creditor must ensure that (i) a Custody Instruction is submitted on their behalf by the **Custody Instruction Deadline** (being 7:00 a.m. (Cayman Islands time)/8:00 p.m. (Hong Kong time) on 29 November 2021) (in accordance with the instructions set out in the Account Holder Letter and Solicitation Packet), and (ii) the Account Holder Letter, including in particular Part 1 and Part 2 of the Account Holder Letter, have been duly completed and submitted to and received by the Information Agent via the Scheme Website (in accordance with the instructions set out in the Account Holder Letter and Solicitation Packet) by no later than the **Voting Instruction Deadline** (being 7:00 a.m. (Cayman Islands time)/8:00 p.m. (Hong Kong time) on 1 December 2021).

Each Scheme Creditor (or, if a corporation, its duly authorised representative) or its proxy intending to attend the Scheme Meeting will be required to register its attendance at the Scheme Meeting no later than one hour prior to the scheduled start time of the Scheme Meeting. Registration at the Scheme Meeting will commence at 6:00 a.m. (Cayman Islands time)/7:00 p.m. (Hong Kong time) on 3 December 2021.

Any Scheme Creditor or its proxy attending the Scheme Meeting in person must produce a duplicate copy of the Account Holder Letter validly completed and submitted on behalf of that Scheme Creditor together with evidence of corporate authority (in the case of a corporation) (for example, a valid power of attorney and/or board resolutions) and evidence of personal identity (being a valid original passport or other original government-issued photographic identification) at the registration desk. If the appropriate personal identification and authorisation evidence is not produced, that person may not be permitted to attend, or vote at, the Scheme Meeting.

Copies of the Scheme, the Explanatory Statement and the Solicitation Packet (including the Account Holder Letter to be completed by all Scheme Creditors) are available to download from the Scheme Website (<https://sites.dfskingltd.com/yestar>).

Pursuant to the Scheme Convening Order, the Court appointed Michelle Xu of Admiralty Harbour Capital Limited (financial adviser to the Company), or, failing her, another representative of the Hong Kong office of Admiralty Harbour Capital Limited nominated by Ms Xu to act as the Chairperson of the Scheme Meeting and directed the Chairperson in their capacity as the Chairperson of the Scheme Meeting to report the results of the Scheme Meeting to the Court within five (5) days of the date of the Scheme Meeting. The results of the Scheme Meeting will also be made available on the Scheme Website and will be the subject of a public announcement to be published on The Stock Exchange of Hong Kong Limited.

The Scheme will be subject to the subsequent approval and sanction of the Court. The Sanction Hearing is presently scheduled to take place on 10 December 2021. Any Scheme Creditor is entitled (but not obliged) to attend the Sanction Hearing, through legal counsel, to support or oppose the sanction of the Scheme.

**FOR ASSISTANCE, PLEASE CONTACT**

**D.F. King Ltd**

Attention: D.F. King Debt Team

Telephone: in Hong Kong +852 3953 7208; in London: +44 20 7920 9700;

Email: [yestar@dfkingltd.com](mailto:yestar@dfkingltd.com)

Scheme Website: <https://sites.dfkingltd.com/yestar>

By Order of the Board

**Yestar Healthcare Holdings Company Limited**

**Hartono James**

*Chairman, CEO and Executive Director*

8 November 2021

*As at the date of this announcement, the executive Directors are Mr. Hartono James, Ms. Wang Ying, Ms. Wang Hong, Ms. Liao Changxiang and Mr. Li Bin; and the independent non-executive Directors are Dr. Hu Yiming, Mr. Zeng Jinsong and Mr. Sutikno Liky.*